Pulmatrix Q2 Loss Narrows to $1.04M as Cash Drops to $2.2M; Merger with Eos SENOLYTIX Expected Q3
PULM sits 36% above its 52-week low of $1.16 on light trading volume (0.1× avg).
Summary
Pulmatrix reported a Q2 net loss of $1.04 million, or $0.29 per share, narrowing from the prior year as general and administrative expenses declined. Cash fell to $2.2 million, and the company reiterated a going concern warning, making the pending reverse merger with Eos SENOLYTIX its only clear path to survival. Management expects the merger to close in Q3 2026 and believes current cash is sufficient to fund operations through that closing. All clinical development remains on hold while the company seeks to license or monetize its clinical assets. This follows the S-4 filing in July detailing the merger terms, which would leave legacy Pulmatrix holders with only 6% of the combined company.
At the time of this announcement, PULM was trading at $1.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $1.16 to $5.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.